首页 > 最新文献

Seminars in Ophthalmology最新文献

英文 中文
Lacrimal History - Part 77: Doyens of Dacryology Series - Jakob Stilling (1842-1915) and Charles Hermon Thomas and the Early Concepts of Lacrimal Stricturoplasty Using Stricturotomoes. 泪道历史-第77部分:泪道学系列-雅各布·斯蒂尔林(1842-1915)和查尔斯·赫尔蒙·托马斯以及使用泪道狭窄切开术的泪道狭窄成形术的早期概念。
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-11-18 DOI: 10.1080/08820538.2025.2589607
Mohammad Javed Ali
{"title":"Lacrimal History - Part 77: Doyens of Dacryology Series - Jakob Stilling (1842-1915) and Charles Hermon Thomas and the Early Concepts of Lacrimal Stricturoplasty Using Stricturotomoes.","authors":"Mohammad Javed Ali","doi":"10.1080/08820538.2025.2589607","DOIUrl":"https://doi.org/10.1080/08820538.2025.2589607","url":null,"abstract":"","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-6"},"PeriodicalIF":2.3,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145550093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lacrimal History - Part 76: Doyens of Dacryology Series - Richard Alexander Norton Welham (1936-). 泪史-第76部分:泪学系列的作家-理查德·亚历山大·诺顿·威尔汉姆(1936-)。
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-11-18 DOI: 10.1080/08820538.2025.2589606
Mohammad Javed Ali, Bhupendra C K Patel
{"title":"Lacrimal History - Part 76: Doyens of Dacryology Series - Richard Alexander Norton Welham (1936-).","authors":"Mohammad Javed Ali, Bhupendra C K Patel","doi":"10.1080/08820538.2025.2589606","DOIUrl":"https://doi.org/10.1080/08820538.2025.2589606","url":null,"abstract":"","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-4"},"PeriodicalIF":2.3,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145550057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the Endoscopic Jones Primary Dye Test in Lacrimal Dysfunction. 评价内窥镜琼斯原色染色试验在泪道功能障碍中的应用。
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-11-17 DOI: 10.1080/08820538.2025.2588716
Carmelo Z Macri, Jessica Y Tong, Abdullah I Almater, Dinesh Selva

Purpose: To evaluate the diagnostic performance of the endoscopic Jones (eJones) I and II tests in patients presenting with epiphora.

Methods: A retrospective review was conducted of patients assessed for epiphora in a tertiary oculoplastic unit. All patients underwent rigid nasal endoscopy, dacryocystography (DCG), and dacryoscintigraphy (DSG). Lacrimal drainage status was categorized as nasolacrimal duct obstruction (NLDO), nasolacrimal duct stenosis (NLDS), or functional epiphora based on imaging findings. eJones I and II test outcomes were compared across diagnostic groups.

Results: Thirty-five symptomatic eyes were included. Functional epiphora was identified in 17 eyes, NLDO in 13 eyes, NLDS in one eye, and four eyes demonstrated normal lacrimal systems. All eyes with NLDO or NLDS had negative eJones I results, while all symptomatic eyes with normal imaging findings had positive eJones I results. Eyes with functional epiphora showed mixed eJones I outcomes.

Conclusions: The eJones I test reliably confirmed anatomical obstruction but yielded variable results in cases of functional epiphora, highlighting the multifactorial mechanisms underlying this condition. Further studies are warranted to validate and refine the diagnostic utility of eJones testing.

目的:评价内窥镜琼斯(eJones) I和II试验对外溢患者的诊断效果。方法:回顾性分析了在三级眼整形单位评估的外溢患者。所有患者均行硬性鼻内窥镜检查、泪囊造影(DCG)和泪囊造影(DSG)检查。泪道引流情况根据影像学表现分为鼻泪管阻塞(NLDO)、鼻泪管狭窄(NLDS)或功能性泪溢。比较不同诊断组的eJones I和II测试结果。结果:纳入35只有症状的眼。17眼发现功能性显泪,13眼发现NLDO, 1眼发现NLDS, 4眼显示泪系统正常。所有患有NLDO或NLDS的眼睛eJones I结果均为阴性,而所有有症状且影像学表现正常的眼睛eJones I结果均为阳性。功能性外显眼的eJones I结果参差不齐。结论:eJones I试验可靠地证实了解剖性梗阻,但在功能性上显的病例中结果不同,强调了这种情况下的多因素机制。需要进一步的研究来验证和完善eJones检测的诊断效用。
{"title":"Evaluating the Endoscopic Jones Primary Dye Test in Lacrimal Dysfunction.","authors":"Carmelo Z Macri, Jessica Y Tong, Abdullah I Almater, Dinesh Selva","doi":"10.1080/08820538.2025.2588716","DOIUrl":"https://doi.org/10.1080/08820538.2025.2588716","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the diagnostic performance of the endoscopic Jones (eJones) I and II tests in patients presenting with epiphora.</p><p><strong>Methods: </strong>A retrospective review was conducted of patients assessed for epiphora in a tertiary oculoplastic unit. All patients underwent rigid nasal endoscopy, dacryocystography (DCG), and dacryoscintigraphy (DSG). Lacrimal drainage status was categorized as nasolacrimal duct obstruction (NLDO), nasolacrimal duct stenosis (NLDS), or functional epiphora based on imaging findings. eJones I and II test outcomes were compared across diagnostic groups.</p><p><strong>Results: </strong>Thirty-five symptomatic eyes were included. Functional epiphora was identified in 17 eyes, NLDO in 13 eyes, NLDS in one eye, and four eyes demonstrated normal lacrimal systems. All eyes with NLDO or NLDS had negative eJones I results, while all symptomatic eyes with normal imaging findings had positive eJones I results. Eyes with functional epiphora showed mixed eJones I outcomes.</p><p><strong>Conclusions: </strong>The eJones I test reliably confirmed anatomical obstruction but yielded variable results in cases of functional epiphora, highlighting the multifactorial mechanisms underlying this condition. Further studies are warranted to validate and refine the diagnostic utility of eJones testing.</p>","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-4"},"PeriodicalIF":2.3,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145542347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual Margins on Autofluorescence in Tubercular Serpiginous-Like Choroiditis: A Biomarker for Increased Risk of Paradoxical Worsening and the Need for Immunosuppression. 结核丝状样脉络膜炎的双边缘自身荧光:一种增加矛盾恶化风险和需要免疫抑制的生物标志物。
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-11-14 DOI: 10.1080/08820538.2025.2588206
Navya Cherukuri, Avinash Pathengay, Mudit Tyagi, Sai Bhakti Mishra, Soumyava Basu, Rajeev R Pappuru

Purpose: To assess the prognostic role of dual margins on fundus autofluorescence (AF) in predicting treatment outcomes in tubercular serpiginous-like choroiditis (TB SLC).

Design: Retrospective interventional study.

Methods: Patients with active TB SLC demonstrating dual hyperautofluorescent margins with an intervening hypoautofluorescent zone on baseline AF, positive laboratory evidence of tuberculosis, radiological evidence of active or healed TB, and ≥3 months follow-up were included. Each case was matched with three controls without dual margins. All patients received oral corticosteroids (prednisolone 1 mg/kg, tapered over 1-2 months) with concurrent antitubercular therapy. Primary outcomes were paradoxical worsening (PW), recurrence, and need for additional immunosuppression. Logistic regression was used to analyze risk factors for PW.

Results: Three hundred and sixty-six patients of active SLC were screened and twenty-one cases and 63 controls were evaluated. PW occurred significantly more often in the dual-margin group (47.6% vs. 14.3%, p = .002). Recurrence rates were comparable (9% vs. 6%, p = .63). Escalation of immunosuppression, including increased corticosteroid use or additional immunomodulatory therapy, was required more frequently in cases (47.6% vs. 20.6%, p = .01).

Conclusion: Dual AF margins may serve as an imaging biomarker of aggressive TB SLC and may predict higher risk of PW and greater immunosuppressive requirements. Early recognition may facilitate closer follow-up and timely therapeutic escalation.

目的:探讨双边缘眼底自身荧光(AF)在预测结核丝状样脉络膜炎(TB SLC)治疗结果中的预后作用。设计:回顾性介入研究。方法:包括在基线房颤上表现出双重高自体荧光边缘和中间低自体荧光区域的活动性TB SLC患者,结核病的实验室证据阳性,结核病活动性或治愈的放射证据,随访≥3个月。每个病例与三个没有双空白的对照相匹配。所有患者均接受口服皮质类固醇(强的松龙1 mg/kg, 1-2个月逐渐减少),同时接受抗结核治疗。主要结局是矛盾性恶化(PW)、复发和需要额外的免疫抑制。采用Logistic回归分析PW的危险因素。结果:筛选出活动性SLC患者366例,评价21例和63例对照。双切缘组PW的发生率明显更高(47.6%比14.3%,p = 0.002)。复发率具有可比性(9%对6%,p = 0.63)。免疫抑制的升级,包括增加皮质类固醇的使用或额外的免疫调节治疗,在病例中更频繁地被要求(47.6%对20.6%,p = 0.01)。结论:双AF缘可作为侵袭性TB SLC的成像生物标志物,并可预测PW的高风险和更高的免疫抑制需求。早期识别可能有助于更密切的随访和及时的治疗升级。
{"title":"Dual Margins on Autofluorescence in Tubercular Serpiginous-Like Choroiditis: A Biomarker for Increased Risk of Paradoxical Worsening and the Need for Immunosuppression.","authors":"Navya Cherukuri, Avinash Pathengay, Mudit Tyagi, Sai Bhakti Mishra, Soumyava Basu, Rajeev R Pappuru","doi":"10.1080/08820538.2025.2588206","DOIUrl":"https://doi.org/10.1080/08820538.2025.2588206","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the prognostic role of dual margins on fundus autofluorescence (AF) in predicting treatment outcomes in tubercular serpiginous-like choroiditis (TB SLC).</p><p><strong>Design: </strong>Retrospective interventional study.</p><p><strong>Methods: </strong>Patients with active TB SLC demonstrating dual hyperautofluorescent margins with an intervening hypoautofluorescent zone on baseline AF, positive laboratory evidence of tuberculosis, radiological evidence of active or healed TB, and ≥3 months follow-up were included. Each case was matched with three controls without dual margins. All patients received oral corticosteroids (prednisolone 1 mg/kg, tapered over 1-2 months) with concurrent antitubercular therapy. Primary outcomes were paradoxical worsening (PW), recurrence, and need for additional immunosuppression. Logistic regression was used to analyze risk factors for PW.</p><p><strong>Results: </strong>Three hundred and sixty-six patients of active SLC were screened and twenty-one cases and 63 controls were evaluated. PW occurred significantly more often in the dual-margin group (47.6% vs. 14.3%, <i>p</i> = .002). Recurrence rates were comparable (9% vs. 6%, <i>p</i> = .63). Escalation of immunosuppression, including increased corticosteroid use or additional immunomodulatory therapy, was required more frequently in cases (47.6% vs. 20.6%, <i>p</i> = .01).</p><p><strong>Conclusion: </strong>Dual AF margins may serve as an imaging biomarker of aggressive TB SLC and may predict higher risk of PW and greater immunosuppressive requirements. Early recognition may facilitate closer follow-up and timely therapeutic escalation.</p>","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-7"},"PeriodicalIF":2.3,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Pedigree Study of Leber's Hereditary Optic Neuropathy in Korean Population. 韩国人群Leber遗传性视神经病变的家系研究。
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-11-14 DOI: 10.1080/08820538.2025.2588702
Dong Hee Ha, Ungsoo Samuel Kim

Purpose: To investigate the pedigree-based penetrance analysis in Korean Leber hereditary optic neuropathy (LHON).

Methods: The pedigrees of 32 LHON patients' families were thoroughly examined. Index patients were probands diagnosed by mitochondrial DNA (mtDNA) mutation at the position of 11,778 or 11,484, while secondary cases were affected relatives ascertained through index cases. We identified susceptible and at-risk family members of the index patients. We categorized susceptible individuals as unaffected offsprings connected within the matrilineal lineage and at-risk individual as a susceptible individual under the age of 25. The penetrance rates for family members by their relationship with the index patients were analyzed. The differences in penetrance rates by degree of relationship and sex were also investigated.

Results: Among the 32 families, 29 (90.6%) had the 11,778 mutation, while 3 (9.4%) had the 14,484 mutation. The average penetrance rates were 37.1% for male and 10.2% for female. For Koreans, one previous study reported a ratio of 1.6:1, and in the present study, the ratio was found to be 2.3:1. The total number of individuals at risk was 24 (10 males and 14 females).

Conclusions: This study expands previous research by offering new information on the penetrance of LHON in the Korean population through pedigree analysis.

目的:探讨朝鲜族Leber遗传性视神经病变(LHON)的家系外显率分析。方法:对32例LHON患者进行家谱分析。指标患者为先证者,通过线粒体DNA (mtDNA)突变在11778或11484位点诊断,继发病例为通过指标病例确定的患病亲属。我们确定了指数患者的易感和高危家庭成员。我们将易感个体分为母系谱系内未受影响的后代和25岁以下的易感个体。分析了家族成员与指标患者关系的外显率。此外,还研究了不同亲缘关系和性别的外显率差异。结果:32个家族中有29个(90.6%)突变11778个,3个(9.4%)突变14484个。男性的平均外显率为37.1%,女性为10.2%。在韩国,以前的研究结果是1.6比1,这次的研究结果是2.3比1。共有24人(男性10人,女性14人)。结论:本研究通过家谱分析提供了韩国人群中LHON外显率的新信息,从而扩展了先前的研究。
{"title":"The Pedigree Study of Leber's Hereditary Optic Neuropathy in Korean Population.","authors":"Dong Hee Ha, Ungsoo Samuel Kim","doi":"10.1080/08820538.2025.2588702","DOIUrl":"https://doi.org/10.1080/08820538.2025.2588702","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the pedigree-based penetrance analysis in Korean Leber hereditary optic neuropathy (LHON).</p><p><strong>Methods: </strong>The pedigrees of 32 LHON patients' families were thoroughly examined. Index patients were probands diagnosed by mitochondrial DNA (mtDNA) mutation at the position of 11,778 or 11,484, while secondary cases were affected relatives ascertained through index cases. We identified susceptible and at-risk family members of the index patients. We categorized susceptible individuals as unaffected offsprings connected within the matrilineal lineage and at-risk individual as a susceptible individual under the age of 25. The penetrance rates for family members by their relationship with the index patients were analyzed. The differences in penetrance rates by degree of relationship and sex were also investigated.</p><p><strong>Results: </strong>Among the 32 families, 29 (90.6%) had the 11,778 mutation, while 3 (9.4%) had the 14,484 mutation. The average penetrance rates were 37.1% for male and 10.2% for female. For Koreans, one previous study reported a ratio of 1.6:1, and in the present study, the ratio was found to be 2.3:1. The total number of individuals at risk was 24 (10 males and 14 females).</p><p><strong>Conclusions: </strong>This study expands previous research by offering new information on the penetrance of LHON in the Korean population through pedigree analysis.</p>","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-5"},"PeriodicalIF":2.3,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology, Associations, and Treatment of Acute Exudative Polymorphous Vitelliform Maculopathy (AEPVM). 急性渗出性多形性黄斑病(AEPVM)的流行病学、相关性和治疗。
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-11-13 DOI: 10.1080/08820538.2025.2583074
Tobin Smith, Vivian Rajeswaren, Brittany Hodges, Pradeepa Yoganathan

Purpose: Acute Exudative Polymorphous Vitelliform Maculopathy (AEPVM) is a rare retinal disorder characterized by serous subretinal detachments that progress to vitelliform lesions. In this review, we aim to summarize current knowledge of etiologies and treatments for AEPVM and its association with primary and recurrent melanoma.

Methods: We performed a comprehensive search of scientific literature for articles mentioning Acute Exudative Polymorphous Vitelliform Maculopathy including all literature published through March 2025 using the online electronic databases PubMed, MEDLINE, and Embase.

Results: We identified 81 cases (mean age 46 ± 16.9 years, 43.2% female) with etiologies including idiopathic (43), infectious (10), paraneoplastic (19), and medication-induced (9). Several successful treatments were identified. Local or systemic corticosteroids in 17 eyes improved subretinal fluid and vision in 100% of idiopathic, 50% of infectious, and 40% of medication-induced cases. In paraneoplastic AEPVM, fluid improved with immunotherapy (2 eyes), chemotherapy (2 eyes), intravitreal methotrexate (1 eye), and aflibercept (2 eyes). Notably, AEPVM was the initial symptom of primary or metastatic melanoma in 5 cases.

Conclusion: The variable response to treatment and the potential link between AEPVM and primary and recurrent melanoma highlights the need for further research. A thorough understanding of treatment options and outcomes is essential to optimize management and to encourage prompt recognition of metastatic melanoma or other conditions associated with AEPVM.

目的:急性渗出性多形性黄斑病变(AEPVM)是一种罕见的视网膜疾病,其特征是浆液性视网膜下脱离进展为黄斑病变。在这篇综述中,我们旨在总结目前关于AEPVM的病因和治疗及其与原发性和复发性黑色素瘤的关系的知识。方法:我们使用PubMed、MEDLINE和Embase在线电子数据库,对涉及急性渗出性多形黄斑病的文章进行了全面的科学文献检索,包括截至2025年3月发表的所有文献。结果:81例患者(平均年龄46±16.9岁,女性43.2%),病因包括特发性(43例)、感染性(10例)、副肿瘤性(19例)和药物诱导(9例)。确定了几种成功的治疗方法。在100%的特发性病例、50%的感染性病例和40%的药物诱导病例中,17只眼局部或全身使用皮质类固醇可改善视网膜下液和视力。在副肿瘤性AEPVM中,通过免疫治疗(2眼)、化疗(2眼)、玻璃体内甲氨蝶呤(1眼)和阿布利塞普(2眼),液体得到改善。值得注意的是,AEPVM是5例原发性或转移性黑色素瘤的初始症状。结论:对治疗的不同反应以及AEPVM与原发性和复发性黑色素瘤之间的潜在联系表明需要进一步研究。全面了解治疗方案和结果对于优化管理和鼓励及时识别转移性黑色素瘤或与AEPVM相关的其他疾病至关重要。
{"title":"Epidemiology, Associations, and Treatment of Acute Exudative Polymorphous Vitelliform Maculopathy (AEPVM).","authors":"Tobin Smith, Vivian Rajeswaren, Brittany Hodges, Pradeepa Yoganathan","doi":"10.1080/08820538.2025.2583074","DOIUrl":"https://doi.org/10.1080/08820538.2025.2583074","url":null,"abstract":"<p><strong>Purpose: </strong>Acute Exudative Polymorphous Vitelliform Maculopathy (AEPVM) is a rare retinal disorder characterized by serous subretinal detachments that progress to vitelliform lesions. In this review, we aim to summarize current knowledge of etiologies and treatments for AEPVM and its association with primary and recurrent melanoma.</p><p><strong>Methods: </strong>We performed a comprehensive search of scientific literature for articles mentioning Acute Exudative Polymorphous Vitelliform Maculopathy including all literature published through March 2025 using the online electronic databases PubMed, MEDLINE, and Embase.</p><p><strong>Results: </strong>We identified 81 cases (mean age 46 ± 16.9 years, 43.2% female) with etiologies including idiopathic (43), infectious (10), paraneoplastic (19), and medication-induced (9). Several successful treatments were identified. Local or systemic corticosteroids in 17 eyes improved subretinal fluid and vision in 100% of idiopathic, 50% of infectious, and 40% of medication-induced cases. In paraneoplastic AEPVM, fluid improved with immunotherapy (2 eyes), chemotherapy (2 eyes), intravitreal methotrexate (1 eye), and aflibercept (2 eyes). Notably, AEPVM was the initial symptom of primary or metastatic melanoma in 5 cases.</p><p><strong>Conclusion: </strong>The variable response to treatment and the potential link between AEPVM and primary and recurrent melanoma highlights the need for further research. A thorough understanding of treatment options and outcomes is essential to optimize management and to encourage prompt recognition of metastatic melanoma or other conditions associated with AEPVM.</p>","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-15"},"PeriodicalIF":2.3,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Application of Artificial Intelligence in Epiretinal Membrane from Detection to Prognosis Prediction. 人工智能在视网膜前膜从检测到预后预测中的应用。
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-11-10 DOI: 10.1080/08820538.2025.2583072
Muxin Xu, Jianwei Lin, Shirong Chen, Yuqiang Huang

Introduction: Epiretinal membrane (ERM) is a prevalent vitreoretinal interface disorder characterized by fibro-cellular proliferation on the inner retinal surface. The prevalence increases markedly with age, and progressive membrane contraction distorts retinal architecture, producing metamorphopsia and irreversible visual impairment thereby significantly impairing patients' quality of life. This highlights the need for more accurate and efficient diagnostic and therapeutic strategies. Artificial intelligence (AI) has emerged as a promising tool to address such challenges. This review summarizes and evaluates recent studies on the applications of AI in ERM management, identifying current limitations and future research directions.

Methods: A comprehensive literature search was conducted in PubMed, Web of Science, Embase, and Cochrane Library databases, focusing on studies related to AI and ERM published over the past decade.

Results: The findings indicate that while research on treatment and prognosis prediction remains limited, and new technologies are expected in image processing, current AI models demonstrate substantial potential in the ERM management, especially in detection and diagnosis.

Discussions: Nonetheless, current evidence is constrained by challenges such as single-center design, limited external validation across devices or ethnicities, insufficient multimodal imaging, and lack of health-economic or workflow integration data. Future multicenter prospective studies, federated learning platforms, publicly annotated imaging dataset and cost-effectiveness analyses are warranted to develop robust, generalizable models that can be seamlessly integrated into clinical workflows, substantially optimizing ERM management and delivering tangible benefits to both patients and clinical practice.

视网膜外膜(ERM)是一种常见的玻璃体视网膜界面疾病,其特征是视网膜内表面纤维细胞增生。随着年龄的增长,患病率明显增加,进行性膜收缩使视网膜结构扭曲,产生变形和不可逆的视力损害,从而严重影响患者的生活质量。这突出表明需要更准确和有效的诊断和治疗策略。人工智能(AI)已经成为解决这些挑战的一个有前途的工具。本文对人工智能在ERM管理中的应用研究进行了总结和评价,指出了当前的局限性和未来的研究方向。方法:在PubMed、Web of Science、Embase和Cochrane Library数据库中进行全面的文献检索,重点检索近十年来发表的与人工智能和ERM相关的研究。结果:研究结果表明,尽管在治疗和预后预测方面的研究仍然有限,并且在图像处理方面有望采用新技术,但目前的人工智能模型在ERM管理方面,特别是在检测和诊断方面显示出巨大的潜力。讨论:尽管如此,目前的证据受到诸如单中心设计、跨设备或种族的有限外部验证、多模式成像不足以及缺乏健康经济或工作流程集成数据等挑战的限制。未来的多中心前瞻性研究、联合学习平台、公开注释的成像数据集和成本效益分析有必要开发强大的、可推广的模型,这些模型可以无缝集成到临床工作流程中,从而大大优化ERM管理,并为患者和临床实践带来切实的好处。
{"title":"The Application of Artificial Intelligence in Epiretinal Membrane from Detection to Prognosis Prediction.","authors":"Muxin Xu, Jianwei Lin, Shirong Chen, Yuqiang Huang","doi":"10.1080/08820538.2025.2583072","DOIUrl":"https://doi.org/10.1080/08820538.2025.2583072","url":null,"abstract":"<p><strong>Introduction: </strong>Epiretinal membrane (ERM) is a prevalent vitreoretinal interface disorder characterized by fibro-cellular proliferation on the inner retinal surface. The prevalence increases markedly with age, and progressive membrane contraction distorts retinal architecture, producing metamorphopsia and irreversible visual impairment thereby significantly impairing patients' quality of life. This highlights the need for more accurate and efficient diagnostic and therapeutic strategies. Artificial intelligence (AI) has emerged as a promising tool to address such challenges. This review summarizes and evaluates recent studies on the applications of AI in ERM management, identifying current limitations and future research directions.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in PubMed, Web of Science, Embase, and Cochrane Library databases, focusing on studies related to AI and ERM published over the past decade.</p><p><strong>Results: </strong>The findings indicate that while research on treatment and prognosis prediction remains limited, and new technologies are expected in image processing, current AI models demonstrate substantial potential in the ERM management, especially in detection and diagnosis.</p><p><strong>Discussions: </strong>Nonetheless, current evidence is constrained by challenges such as single-center design, limited external validation across devices or ethnicities, insufficient multimodal imaging, and lack of health-economic or workflow integration data. Future multicenter prospective studies, federated learning platforms, publicly annotated imaging dataset and cost-effectiveness analyses are warranted to develop robust, generalizable models that can be seamlessly integrated into clinical workflows, substantially optimizing ERM management and delivering tangible benefits to both patients and clinical practice.</p>","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-10"},"PeriodicalIF":2.3,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lacrimal History - Part 75: Doyens of Dacryology Series - Fano Salvador (1824-1895) and His Lacrimal Pump Device, Concepts of Lacrimal Sac Catarrh and Its Histology. 泪史-第75部分:泪学系列的几十年-法诺·萨尔瓦多(1824-1895)和他的泪泵装置,泪囊黏膜炎及其组织学的概念。
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-11-06 DOI: 10.1080/08820538.2025.2585700
Mohammad Javed Ali
{"title":"Lacrimal History - Part 75: Doyens of Dacryology Series - Fano Salvador (1824-1895) and His Lacrimal Pump Device, Concepts of Lacrimal Sac Catarrh and Its Histology.","authors":"Mohammad Javed Ali","doi":"10.1080/08820538.2025.2585700","DOIUrl":"https://doi.org/10.1080/08820538.2025.2585700","url":null,"abstract":"","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-8"},"PeriodicalIF":2.3,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145458982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lacrimal History - Part 78: Doyens of Dacryology Series - Ferdinand Leopold Kersten (1804-1853) and His 1828 Doctoral Thesis on Dacryoliths. 泪史-第78部分:泪学系列-费迪南德·利奥波德·克斯滕(1804-1853)和他1828年关于泪石的博士论文。
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-11-06 DOI: 10.1080/08820538.2025.2585715
Mohammad Javed Ali
{"title":"Lacrimal History - Part 78: Doyens of Dacryology Series - Ferdinand Leopold Kersten (1804-1853) and His 1828 Doctoral Thesis on Dacryoliths.","authors":"Mohammad Javed Ali","doi":"10.1080/08820538.2025.2585715","DOIUrl":"https://doi.org/10.1080/08820538.2025.2585715","url":null,"abstract":"","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-4"},"PeriodicalIF":2.3,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145459366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancements and Collaborative Dynamics in the Treatment of Retinoblastoma: A Bibliometric Analysis of Trends and Themes. 视网膜母细胞瘤治疗的进展和合作动态:趋势和主题的文献计量学分析。
IF 2.3 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-11-05 DOI: 10.1080/08820538.2025.2584513
Jinying Gao, Peng Huang, Xue Leng, Yibing Zhang

Aim: This study aimed to provide a comprehensive bibliometric analysis of retinoblastoma treatment, assessing publication trends, influential research, and leading contributors.

Methods: The research was conducted using the Web of Science Core Collection, focusing on retinoblastoma treatment from January 1, 1941, to June 13, 2024. Bibliometric analysis were conducted using Microsoft Excel, VOSviewer, CiteSpace, and the Bibliometrics R package.

Results: The analysis identified 5,674 documents. The United States led in research output and citation impact, followed by China and Europe. The University of Toronto was the most prolific institution (488 articles). International collaborations accounted for 18.54% of publications. David H. Abramson was the most prolific author (139 articles), followed closely by C.L. Shields (100 articles). Keyword analysis revealed three major thematic clusters: (1) molecular mechanisms and oncogenesis, (2) cell cycle regulation and experimental models, and (3) clinical management and therapeutic strategies. Recent hotspots included intraarterial chemotherapy, melphalan, treatment resistance, risk stratification, and tumor biology. Retinoblastoma research centers on molecular mechanisms, cell cycle regulation, and clinical management.

Conclusion: Advances in intraarterial chemotherapy, risk assessment, and molecular insights are improving survival and quality of life. Greater emphasis on real-world, multicenter, and international studies is needed to advance personalized care.

目的:本研究旨在提供视网膜母细胞瘤治疗的综合文献计量分析,评估出版趋势、有影响力的研究和主要贡献者。方法:研究使用Web of Science核心馆藏进行,重点关注1941年1月1日至2024年6月13日期间视网膜母细胞瘤的治疗。使用Microsoft Excel、VOSviewer、CiteSpace和bibliometics R软件包进行文献计量学分析。结果:共鉴定出5674份文献。美国在研究产出和引文影响方面领先,其次是中国和欧洲。多伦多大学是发表论文最多的大学(488篇)。国际合作占18.54%。大卫·h·艾布拉姆森(David H. Abramson)是最多产的作者(139篇文章),其次是C.L.希尔兹(100篇文章)。关键词分析揭示了三个主要主题集群:(1)分子机制和肿瘤发生;(2)细胞周期调控和实验模型;(3)临床管理和治疗策略。最近的热点包括动脉化疗、美法兰、治疗耐药性、风险分层和肿瘤生物学。视网膜母细胞瘤的研究主要集中在分子机制、细胞周期调控和临床管理方面。结论:动脉内化疗、风险评估和分子洞察的进展正在改善生存率和生活质量。需要更多地强调现实世界、多中心和国际研究来推进个性化护理。
{"title":"Advancements and Collaborative Dynamics in the Treatment of Retinoblastoma: A Bibliometric Analysis of Trends and Themes.","authors":"Jinying Gao, Peng Huang, Xue Leng, Yibing Zhang","doi":"10.1080/08820538.2025.2584513","DOIUrl":"https://doi.org/10.1080/08820538.2025.2584513","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to provide a comprehensive bibliometric analysis of retinoblastoma treatment, assessing publication trends, influential research, and leading contributors.</p><p><strong>Methods: </strong>The research was conducted using the Web of Science Core Collection, focusing on retinoblastoma treatment from January 1, 1941, to June 13, 2024. Bibliometric analysis were conducted using Microsoft Excel, VOSviewer, CiteSpace, and the Bibliometrics R package.</p><p><strong>Results: </strong>The analysis identified 5,674 documents. The United States led in research output and citation impact, followed by China and Europe. The University of Toronto was the most prolific institution (488 articles). International collaborations accounted for 18.54% of publications. David H. Abramson was the most prolific author (139 articles), followed closely by C.L. Shields (100 articles). Keyword analysis revealed three major thematic clusters: (1) molecular mechanisms and oncogenesis, (2) cell cycle regulation and experimental models, and (3) clinical management and therapeutic strategies. Recent hotspots included intraarterial chemotherapy, melphalan, treatment resistance, risk stratification, and tumor biology. Retinoblastoma research centers on molecular mechanisms, cell cycle regulation, and clinical management.</p><p><strong>Conclusion: </strong>Advances in intraarterial chemotherapy, risk assessment, and molecular insights are improving survival and quality of life. Greater emphasis on real-world, multicenter, and international studies is needed to advance personalized care.</p>","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-13"},"PeriodicalIF":2.3,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145452933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Seminars in Ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1